MX2015012074A - Composicion farmaceutica de mesalamina con multiples elementos de dosis para viabilidad de administracion reducida. - Google Patents
Composicion farmaceutica de mesalamina con multiples elementos de dosis para viabilidad de administracion reducida.Info
- Publication number
- MX2015012074A MX2015012074A MX2015012074A MX2015012074A MX2015012074A MX 2015012074 A MX2015012074 A MX 2015012074A MX 2015012074 A MX2015012074 A MX 2015012074A MX 2015012074 A MX2015012074 A MX 2015012074A MX 2015012074 A MX2015012074 A MX 2015012074A
- Authority
- MX
- Mexico
- Prior art keywords
- mesalamine
- pharmaceutical composition
- multiple dosage
- reduced delivery
- dosage element
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica de mesalamina con variabilidad de administración reducida para administración de mesalamina al colon que incluye múltiples elementos de dosis, y cada elemento de dosis incluye mesalamina y un revestimiento entérico. El revestimiento entérico de cada elemento de dosis difiere de modo que el punto de liberación de la mesalamina en el tracto GI se varía. En una modalidad, un primer elemento de dosis libera aproximadamente 30% a aproximadamente 60% en peso de la mesalamina total en la composición después de 60 minutos a un pH de aproximadamente 6.6 en una amortiguador acuoso de fosfato usando un aparato 2 de paletas con una velocidad de paletas de 100 rpm y un segundo elemento de dosis libera aproximadamente 40% a aproximadamente 70% en peso de la mesalamina total después de 60 minutos a un pH de aproximadamente 7.2 en una amortiguador acuoso de fosfato usando un aparato 2 de paletas con un velocidad de paletas de 100 rpm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794998P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027353 WO2014152450A1 (en) | 2013-03-15 | 2014-03-14 | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012074A true MX2015012074A (es) | 2016-05-10 |
Family
ID=50588880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012074A MX2015012074A (es) | 2013-03-15 | 2014-03-14 | Composicion farmaceutica de mesalamina con multiples elementos de dosis para viabilidad de administracion reducida. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9763887B2 (es) |
| EP (1) | EP2953619A1 (es) |
| JP (1) | JP6294457B2 (es) |
| CN (1) | CN105307644B (es) |
| AU (1) | AU2014239683B2 (es) |
| CA (1) | CA2905467C (es) |
| HK (1) | HK1218856A1 (es) |
| IL (1) | IL241376A0 (es) |
| MX (1) | MX2015012074A (es) |
| WO (1) | WO2014152450A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7021108B2 (ja) | 2016-04-19 | 2022-02-16 | コナリス リサーチ インスティテュート アクチェンゲゼルシャフト | ニコチンアミドの経口薬学的組成物 |
| RU2744576C2 (ru) * | 2016-04-19 | 2021-03-11 | Ферринг Б.В. | Пероральные фармацевтические композиции месалазина |
| WO2022245307A1 (en) * | 2021-05-21 | 2022-11-24 | Ilko Ilac Sanayi Ve Ticaret A.S. | Composition of mesalazine enteric tablet formulation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| IL77186A0 (en) | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
| IT1230576B (it) | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5316772A (en) | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
| GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
| ES2176209T3 (es) | 1992-11-06 | 2002-12-01 | Hisamitsu Pharmaceutical Co | Preparacion farmaceutica oral liberable en el tracto digestivo inferior. |
| US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US5482718A (en) | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| US5686106A (en) | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| ITMI991316A1 (it) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
| IT1318625B1 (it) * | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
| AU2000265525A1 (en) | 2000-08-29 | 2002-03-13 | Mepha Ag | Medicament for treating intestinal diseases |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| PL201766B1 (pl) * | 2001-01-31 | 2009-05-29 | Roehm Gmbh | Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie |
| EP2334178A4 (en) | 2008-10-03 | 2012-04-11 | Falk Pharma Gmbh | COMPOSITIONS AND METHODS OF TREATING THERAPEUTIC DISEASES WITH GRANULATED MESALAMINE |
| WO2010077908A1 (en) * | 2008-12-17 | 2010-07-08 | Altheus Therapeutics, Inc. | Oral formulations |
-
2014
- 2014-03-14 JP JP2016502411A patent/JP6294457B2/ja not_active Expired - Fee Related
- 2014-03-14 AU AU2014239683A patent/AU2014239683B2/en not_active Ceased
- 2014-03-14 MX MX2015012074A patent/MX2015012074A/es unknown
- 2014-03-14 WO PCT/US2014/027353 patent/WO2014152450A1/en active Application Filing
- 2014-03-14 EP EP14719975.6A patent/EP2953619A1/en not_active Ceased
- 2014-03-14 CA CA2905467A patent/CA2905467C/en active Active
- 2014-03-14 CN CN201480022816.2A patent/CN105307644B/zh not_active Expired - Fee Related
- 2014-03-14 US US14/210,850 patent/US9763887B2/en active Active
-
2015
- 2015-09-09 IL IL241376A patent/IL241376A0/en unknown
-
2016
- 2016-06-14 HK HK16106844.7A patent/HK1218856A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL241376A0 (en) | 2015-11-30 |
| CN105307644B (zh) | 2019-07-23 |
| AU2014239683A1 (en) | 2015-10-22 |
| US9763887B2 (en) | 2017-09-19 |
| US20140271859A1 (en) | 2014-09-18 |
| CA2905467C (en) | 2019-11-12 |
| JP2016513693A (ja) | 2016-05-16 |
| CN105307644A (zh) | 2016-02-03 |
| JP6294457B2 (ja) | 2018-03-14 |
| AU2014239683B2 (en) | 2018-05-17 |
| HK1218856A1 (zh) | 2017-03-17 |
| CA2905467A1 (en) | 2014-09-25 |
| WO2014152450A1 (en) | 2014-09-25 |
| EP2953619A1 (en) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1040I1 (fr) | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations | |
| IL250752B (en) | Device with compounds for conduction to lungs, oral mucosa and brain | |
| IL292262A (en) | Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CL2014001930A1 (es) | Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2). | |
| TR201903569T4 (tr) | Bir gecikmeli salım ilaç formülasyonu. | |
| DK3216448T3 (da) | Paraciticide orale veterinære sammensætninger omfattende systemisk-virkende aktivstoffer, fremgangsmåder og anvendelser deraf | |
| EP3904502A3 (en) | Compositions and methods | |
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| FR3002736B1 (fr) | Composition orale nutritionnelle et medicamenteuse a usage veterinaire | |
| EP3166648A4 (en) | Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations | |
| BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| ZA201508454B (en) | Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| MX2015012074A (es) | Composicion farmaceutica de mesalamina con multiples elementos de dosis para viabilidad de administracion reducida. | |
| HK1218622A1 (zh) | 含有改性瓜爾膠的藥物軟明膠膠囊劑型 | |
| EP3581205A3 (en) | Product and method for treating diarrhea | |
| TR201100150A2 (tr) | Suda çözünür dozaj formları | |
| MX2014006201A (es) | Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse. | |
| MX366936B (es) | Uso de un anticuerpo específico alfa4beta7. | |
| EA201301232A1 (ru) | Лекарственная форма для целевого высвобождения активных веществ | |
| EA201201329A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| NZ628867A (en) | Pharmaceutical formulation containing flupirtine |